Overview

A class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Applied Therapeutics class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, both dates inclusive (the “Class Period”). Investors have until February 18, 2025, to seek appointment as lead plaintiff in the Applied Therapeutics class action lawsuit.

Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases.  The Company’s lead drug candidate, govorestat, is a central nervous system (“CNS”) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.

The Applied Therapeutics class action lawsuit alleges that Defendants, throughout the Class Period, provided investors with material information concerning Applied Therapeutics’s Phase 3 INSPIRE trial results for govorestat and the drug’s efficacy in treating Galactosemia.  Defendants’ statements included, among other things, confidence in the Company’s New Drug Application to the U.S. Food and Drug Administration for govorestat, submission of a Marketing Authorization Authority to the European Medicines Agency for the same, positive clinical outcomes data from the Phase 3 registrational ACTION-Galactosemia Kids study in children age 2-17 with Galactosemia, the Phase 1/2 ACTION-Galactosemia study in adult patients with Galactosemia, and preclinical data as well as positive interim trial results from the Phase 3 INSPIRE trial.  Defendants provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of Applied Therapeutics’s Phase 3 INSPIRE trial; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study.  Such statements absent these material facts caused Plaintiff and other shareholders to purchase Applied Therapeutics’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Applied Therapeutics class action lawsuit is February 18, 2025.